CD274 and non-small cell lung carcinoma: The ORR for PD-L1 + (≥ 1%) patients in the HNSCC and NSCLC cohorts was 16% (90% CI, 4.5–35.9; 3 confirmed PRs in 19 PD-L1 + HNSCC patients) and 13% (90% CI, 2.3–34.4; 2 confirmed PRs in 16 PD-L1 + NSCLC patients), respectively (Table 3).